Stock Information
Lineage Cell Therapeutics Inc (LCTX)
Ticker Symbol: LCTX
Exchange: NYSE
Sector: Biotechnology
Market Cap: $301.40 mil
Piotroski score: 3
PE Ratio: N/A
EPS (TTM): -0.2777
Revenue (TTM): $0.06 M
Dividend Yield: N/A%
ROE: -151.35%
Latest News
-
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan
Tue, Jul 14, 2026 7:02 AM
-
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
Mon, Jul 13, 2026 9:20 PM
-
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
Mon, Jul 13, 2026 12:00 PM
-
Lineage Cell Therapeutics Updates COR1 Corneal Cell Transplant Program; Highlights Scalable Allogeneic Production Via AlloSCOPE Platform And Plans Conference Call Today
Mon, Jul 13, 2026 8:08 AM
Key Financials
Financial data not available
